The HemOnc Pulse
Krish Patel, MD, Talks Glofitamab, Other Novel Therapies in DLBCL
Apr 4, 2024
Dr. Krish Patel from the Swedish Cancer Institute discusses novel therapies for DLBCL, focusing on bispecific antibody gilteritinib. They compare bispecifics to CAR T-cell therapy, explore fixed duration therapy, step-up dosing, and sequencing therapy for optimal results.
22:05
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Frontline therapy shifts towards using Polatuzumab-based therapy for non-GCB DLBCL patients following positive Polaris trial data.
- Bispecific antibodies like Polatuzumab show efficacy in third-line DLBCL treatment with potential for combination therapies.
Deep dives
The Evolution of Frontline Therapy for Diffuse Large B Cell Lymphoma
Frontline therapy for diffuse large B cell lymphoma (DLBCL) has seen significant changes, particularly with the introduction of the Polaris trial data, comparing R-Chop to R-Chop with Polatuzumab. The data showed benefits of Polatuzumab-based therapy, especially in non-germinal center B cell DLBCL. This led to a shift towards using Polatuzumab-based therapy, particularly for non-GCB patients, with ongoing monitoring of the treatment's long-term benefits.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
